Alvotech

Contributing Author

Recent Articles by Alvotech

Aug-31	Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio to subcutaneous presentations ALVO GlobeNewswire
Aug-31	Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio to Subcutaneous Presentations ALVO GlobeNewswire
Aug-27	Alvotech to present at upcoming investor conferences in September ALVO GlobeNewswire
Aug-27	Alvotech to present at upcoming investor conferences in September ALVO GlobeNewswire
Aug-21	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets ALVO GlobeNewswire
Aug-21	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets ALVO GlobeNewswire
Aug-19	Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update ALVO ALVO +7.02% GlobeNewswire
Aug-19	Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update ALVO ALVO +7.02% GlobeNewswire
Aug-10	Alvotech to Report Financial Results for H1 2026 ALVO GlobeNewswire
Aug-10	Alvotech to Report Financial Results for H1 2026 ALVO GlobeNewswire
Jul-29	Alvotech announces successful closure of FDA inspection of manufacturing facility ALVO +13.87% GlobeNewswire
Jul-29	Alvotech announces successful closure of FDA inspection of manufacturing facility ALVO +13.87% GlobeNewswire
Jul-03	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
Jul-01	Alvotech further strengthens liquidity by securing term loan facility of $75 million ALVO GlobeNewswire
Jul-01	Alvotech further strengthens liquidity by securing term loan facility of $75 million ALVO GlobeNewswire
Jun-22	Transactions of Managers and Closely Associated Persons ALVO -6.89% GlobeNewswire
Jun-18	Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement ALVO GlobeNewswire
Jun-18	Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement ALVO GlobeNewswire
Jun-18	Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares ALVO GlobeNewswire
Jun-15	Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement ALVO -8.73% GlobeNewswire
Jun-15	Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement ALVO -8.73% GlobeNewswire
Jun-15	Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares ALVO ALVO -8.73% GlobeNewswire
Jun-15	Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares ALVO ALVO -8.73% GlobeNewswire
Jun-10	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
Jun-08	Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio ALVO +19.77% GlobeNewswire
Jun-08	Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio ALVO +19.77% GlobeNewswire
Jun-04	Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea ALVO +19.11% GlobeNewswire
Jun-04	Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria, and AVT06, a proposed biosimilar to Eylea ALVO +19.11% GlobeNewswire
Jun-03	Main Results of 2026 Annual and Extraordinary General Meeting ALVO GlobeNewswire
Jun-03	Main Results of 2026 Annual and Extraordinary General Meeting ALVO ALVO +19.11% GlobeNewswire
Jun-02	Alvotech to present at upcoming investor conferences in June ALVO -6.83% GlobeNewswire
Jun-02	Alvotech to present at upcoming investor conferences in June ALVO -6.83% GlobeNewswire
Jun-01	Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland ALVO GlobeNewswire
May-11	Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility ALVO +10.12% GlobeNewswire
May-11	Alvotech announces completion of FDA surveillance inspection at Reykjavik facility ALVO +10.12% GlobeNewswire
May-06	Alvotech Q1 2026 Financial Results ALVO ALVO -10.36% GlobeNewswire
May-06	Alvotech Q1 2026 Financial Results ALVO ALVO -10.36% GlobeNewswire
Apr-30	Alvotech Announces a Change in its Executive Team ALVO GlobeNewswire
Apr-30	Alvotech Announces a Change in its Executive Team ALVO GlobeNewswire
Apr-24	Alvotech to Report Financial Results for the First Quarter of 2026 ALVO GlobeNewswire
Apr-24	Alvotech to Report Financial Results for the First Quarter of 2026 ALVO GlobeNewswire
Mar-30	Alvotech files Annual Report with the SEC ALVO +5.79% GlobeNewswire
Mar-30	Alvotech Publishes 2025 Annual Report ALVO +5.79% GlobeNewswire
Mar-30	Alvotech Files Annual Report with the SEC ALVO +5.79% GlobeNewswire
Mar-18	Alvotech Q4 2025 and Full Year 2025 Financial Results ALVO ALVO -5.79% GlobeNewswire
Mar-18	Alvotech Q4 2025 and Full Year 2025 Financial Results ALVO ALVO -5.79% GlobeNewswire
Mar-04	Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results ALVO GlobeNewswire
Mar-04	Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results ALVO GlobeNewswire
Feb-26	Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
Feb-11	Alvotech Announces Increase in Number of Own Shares ALVO -6.73% GlobeNewswire
Feb-05	Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio ALVO GlobeNewswire
Feb-05	Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio ALVO GlobeNewswire
Feb-02	Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates ALVO GlobeNewswire
Feb-02	Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates ALVO GlobeNewswire
Jan-29	Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg ALVO GlobeNewswire
Jan-29	Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg ALVO GlobeNewswire
Jan-07	Correction: Transactions of Managers and Closely Associated Persons ALVO GlobeNewswire
Jan-06	Transactions of Managers and Closely Associated Persons ALVO -6.53% GlobeNewswire
Jan-06	Transactions of Managers and Closely Associated Persons ALVO -6.53% GlobeNewswire
Jan-06	Alvotech announces planned CEO succession and leadership transition ALVO -6.53% GlobeNewswire
Jan-06	Alvotech announces planned CEO succession and leadership transition ALVO -6.53% GlobeNewswire
Dec-31	Alvotech Secures Term Loan Facility of USD 100 Million ALVO GlobeNewswire
Dec-31	Alvotech Secures Term Loan Facility of USD 100 Million ALVO GlobeNewswire
Dec-29	Changes in company's own shares ALVO -5.51% GlobeNewswire
Dec-22	Alvotech's Financial Calendar for 2026 ALVO GlobeNewswire
Dec-22	Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma ALVO GlobeNewswire
Dec-22	Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma ALVO GlobeNewswire
Dec-19	Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea ALVO GlobeNewswire
Dec-19	Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea ALVO GlobeNewswire
Dec-17	Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering ALVO GlobeNewswire
Dec-16	Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance ALVO -6.67% GlobeNewswire
Nov-24	Alvotech Announces Approval of AVT03, a Biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area ALVO +6.42% GlobeNewswire
Nov-24	Alvotech Announces Approval of AVT03, a Biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area ALVO +6.42% GlobeNewswire
Nov-20	Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) ALVO GlobeNewswire
Nov-20	Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab) ALVO GlobeNewswire
Nov-12	Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update ALVO GlobeNewswire
Nov-12	Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update ALVO GlobeNewswire
Nov-10	UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea (aflibercept) ALVO GlobeNewswire
Nov-10	UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea (aflibercept) ALVO GlobeNewswire
Nov-06	Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz, a Biosimilar to Simponi (golimumab), from the MHRA ALVO GlobeNewswire
Nov-06	Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz, a Biosimilar to Simponi (golimumab), from the MHRA ALVO GlobeNewswire
Nov-04	Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update ALVO GlobeNewswire
Nov-04	Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update ALVO GlobeNewswire
Nov-02	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 ALVO GlobeNewswire
Nov-02	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 ALVO GlobeNewswire
Oct-22	Alvotech Announces Changes in Global Business Development and Commercial Operations Team ALVO GlobeNewswire
Oct-22	Alvotech Announces Changes in Global Business Development and Commercial Operations Team ALVO GlobeNewswire
Oct-06	European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency ALVO GlobeNewswire
Oct-06	European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency ALVO GlobeNewswire
Sep-22	European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia and Xgeva ALVO GlobeNewswire
Sep-22	European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia and Xgeva ALVO GlobeNewswire
Sep-22	European Medicines Agency Recommends Marketing Approval of Gobivaz, Alvotech's Proposed Biosimilar to Simponi (golimumab) with Advanz Pharma as Commercialization Partner ALVO GlobeNewswire
Sep-22	European Medicines Agency Recommends Marketing Approval of Gobivaz, Alvotech's Proposed Biosimilar to Simponi (golimumab) with Advanz Pharma as Commercialization Partner ALVO GlobeNewswire
Sep-19	Alvotech Announces Marketing Approval in Japan of Three New Biosimilars ALVO GlobeNewswire
Sep-19	Alvotech Announces Marketing Approval in Japan of Three New Biosimilars ALVO GlobeNewswire
Sep-04	Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York ALVO GlobeNewswire
Sep-04	Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York ALVO GlobeNewswire
Aug-21	Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea ALVO GlobeNewswire
Aug-21	Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea ALVO GlobeNewswire
Aug-20	Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia ALVO -5.41% GlobeNewswire

Alvotech

Recent Articles by Alvotech

Upgrade your Finviz experience